Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 1c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.52, $0.01 better than the analyst estimate of $0.51. Revenue for the quarter came in at $50.1 million versus the consensus estimate of $52.52 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat